Natco Pharma surges 2% on settlement agreement with Celgene

Celgene has agreed to provide Natco with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic Lenalidomide

Dec 23, 2015 04:12 IST India Infoline News Service

Natco Pharma and its US partner Allergan announced settlement of its pending litigation with Celgene regarding generic Lenalidomide.

Celgene has agreed to provide Natco with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic Lenalidomide in the United States beginning on January 31, 2026.

In addition, Natco will receive a volume-limited license to sell generic Lenalidomide in the United States commencing in March 2022. The volume limit is expected to be a mid-single-digit percentage of the total Lenalidomide capsules dispensed in the United States during the first full year of entry.

The volume limitation is expected to increase gradually each 12 months until March of 2025, and is not expected to exceed one-third of the total Lenalidomide capsules dispensed in the US in the final year of the volume-limited license under this agreement.

REVLIMID had recorded sales of nearly US$3.4 billion in the US market for the year ending September 2015, according to Celgene’s website.


The stockj is currently trading 2.21% higher at Rs. 576 on BSE after the company announced that it along with its US partner Allergan entered into settlement agrrement for its pending litigation with Celgene regarding generic Lenalidomide.

The scrip opened higher at Rs. 575 as against its previous close of Rs. 563.65. It hit a high and a low of Rs. 579 and Rs. 568 respectively. So far, 15,000 shares have changed hands on BSE.

Related Story